GLORY-1, phase 3 in China
In a 48-week, double-blind, placebo-controlled phase 3 trial of 610 Chinese adults with overweight or obesity (GLORY-1), both mazdutide groups lost about 10% and 13% of body weight by week 32 versus a 0.5% gain on placebo. By week 48 the losses were about 11% and 14%, and about 36% and 50% of the two groups had lost at least 15%, versus 2% on placebo.
- Study type
- Human trial
- Population
- 610 Chinese adults aged 18 to 75 with BMI 28 or above, or 24 to under 28 with a weight-related condition; phase 3, multicentre, randomised 1:1:1.
- Source
- 1 Ji et al., 2025
Limitation: Sponsor-funded (Innovent Biologics).
Limitations in full
Sponsor-funded (Innovent Biologics). Chinese population only, so results may not carry over to other groups. Abstract read via Europe PMC; full text not read.